The mass-action law based algorithms for quantitative econo-green bio-research

Integrative Biology

Volumn 3, Issue 5, 2011, Pages 548-559

  Chou, Ting Chao ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; CARCINOGEN TESTING; DOSE RESPONSE; EXPERIMENTAL DESIGN; GREEN CHEMISTRY; HUMAN; MASS ACTION; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RISK ASSESSMENT;

ALGORITHMS; CELL PHYSIOLOGICAL PHENOMENA; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GREEN CHEMISTRY TECHNOLOGY; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 79959566594     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c0ib00130a     Document Type: Review

References (38)

1. T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol. Rev., 2006, 58, 621-681. (Free web link: http://pharmrev.aspetjournals.org/cgi/ reprint/58/3/621).
2. T. C. Chou, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands, J. Theor. Biol., 1976, 59, 253-276.
3. T. C. Chou, Combinatorial analysis of multiple substrate-multiple product enzyme reactions, J. Theor. Biol., 1972, 35, 285-297.
4. T. C. Chou, On the determination of availability of ligand binding sites in steady-state systems, J. Theor. Biol., 1977, 65, 345-356.
5. T. C. Chou, Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition, Mol. Pharmacol., 1974, 10, 235-247.
6. T. C. Chou and J. H. Chou, Determination of availability of ligand binding site at steady state for topological assessment of receptors with the aid of microcomputers, Eur. J. Pharmacol., 1990, 183, 921.
7. T. C. Chou, in The median-effect principle and the combination index for quantitation of synergism and antagonism, ed. T. C. Chou and D. C. Rideout, Synergism and Antagonism in Chemotherapy, Academic Press, San Diego, 1991, pp. 61-102.
8. 50, Synergism, Antagonism, Low-Dose Risk, Receptor Ligand Binding and Enzyme Kinetics: Computer Software for the IBM PC Series, Elsevier-Biosoft, Cambridge (UK), 1989.
9. T. C. Chou and M. P. Hayball, CalcuSyn for Windows: Multiple-Drug Dose-Effect Analyzer and Manual, Biosoft, Cambridge (UK), 1997.
10. 50 Values, ComboSyn, Paramus, (NJ), 2005.
11. T. C. Chou, The mass-action law based GPS concept for bioinformatics, Nature Precedings (npre.2008.2064-2); July 22, 2008. Available free at http://precedings.nature.com/documents/2064/version/2.
12. T. C. Chou, Preclinical versus clinical drug combination studies, Leuk. Lymphoma, 2008, 49, 2059-2080.
13. T. C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res., 2010, 70, 440-446.
14. T. C. Chou, On the complement between ancient Chinese philosophy and modern science algorithms, 16th International Conference of Chinese Philosophy, Taipei, July 8-11, 2009 (made available by the Conference Organizer in electronic CD, No. D-16).
15. T. C. Chou, Yijing concept in contemporary mathematics, topology, and sciences, The 13th I-Ching World Conference, Wuxi, China. June 14-17, 2010; p. 642-653.
16. T. C. Chou, Comparison of dose-effect relationships of carcinogens following lose-dose chronic exposure and high-dose single injection: an analysis by the median-effect principle, Carcinogenesis, 1980, 1, 203-213.
17. T. C. Chou and P. Talalay, in Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents, in New Avenues in Developmental Cancer Chemotherapy, ed. K. R. Harrap and T. A. Connors, Academic Press, New York, 1987, pp. 37-64.
18. T. C. Chou, Drug combination against xenograft tumors in nude mice: Experimental design, execution, and computerized simulation of synergism and antagonism (An abstract for the mini-symposium), Proc. Am. Assoc. Cancer Res., 2008, 49, 997.
19. D. Mildvan, et al. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clinical Trial Group 068, Antivir. Ther., 1996, 1, 77-88. (Pubitemid 126690051)
20. T. C. Chou and P. Talalay, Analysis of combined drug effects: a new look at a very old problem, Trends Pharmacol. Sci., 1983, 4, 450-454.
21. T. C. Chou and P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul., 1984, 22, 27-55.
22. T. C. Chou, What is synergy? Scientist, 2007, 21, 15.
23. T. C. Chou, R. J. Motzer, Y. Tong and G. J. Bosl, Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design, J. Natl. Cancer Inst., 1994, 86, 1517-1524. (Pubitemid 24330215)
24. A. Goldin and N. Mantel, The employment of combinations of drugs in the chemotherapy of neoplasia: a review, Cancer Res., 1958, 17, 635-654.
25. W. R. Greco, G. Bravo and J. C. Parsons, The search for synergy: a critical review from a response surface perspective, Pharmacol. Rev., 1995, 47, 331-385.
26. T. C. Chou and P. Talalay, A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems, J. Biol. Chem., 1977, 252, 6438-6442. (Pubitemid 8193791)
27. T. C. Chou and P. Talalay, Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors, Eur. J. Biochem., 1981, 115, 207-216.
28. S. Loewe, Die quantitation probleme der pharmacologie, Ergeb. Physiol., 1928, 27, 47-187.
29. M. C. Berenbaum, What is synergy?, Pharmacol. Rev., 1989, 41, 93-141.
30. J. H. Chou and T. C. Chou, Computerized simulation of dose-reduction index (DRI) in synergistic drug combinations, Pharmacologist, 1988, 30, A231.
31. T. C. Chou and J. Chou, Computerized indexing of drug combinations: prediction of synergism and antagonism of more than two drugs by polygonogram (abstract), FASEB J., 1998, 12, A832.
32. T. C. Chou, et al., Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B, Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 9642-9647.
33. T. C. Chou, et al., Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel, Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 15798-15802.
34. T. C. Chou, et al., The synthesis, discovery and development of a highly promising class of microtubule stabilzation agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice, Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 8113-8118.
35. T. C. Chou, et al., Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, Fludelone, via parenteral or oral route, Cancer Res., 2005, 65, 9445-9454.
36. T. C. Chou, et al., Therapeutic cure against human xenograft tumors in nude mice by the third generation microtubule stabilization epothilones, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 13157-13162.
37. + cells per cubic millimeter, N. Engl. J. Med., 1995, 333, 1662-1669.
38. R. Y. Tsien, Constructing and exploiting the fluorescent protein paintbox (Nobel lecture), Angew. Chem., Int. Ed., 2009, 48, 5612-5626.